Text Size

Changes in ocular signs and symptoms in patients switching from bimatoprost-Timolol to tafluprost-Timolol eye drops: An open-label phase IV study

Bourne R.R.A., Kaarniranta K., Lorenz K., Traverso C.E., Vuorinen J., Ropo A.


  • 2019
  • BMJ Open
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Cambridge University Hospitals, Cambridge, United Kingdom; Vision and Eye Research Unit, Anglia Ruskin University, Cambridge, United Kingdom; Department of Ophthalmology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland; Department of Ophthalmology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany; Clinica Oculistica Di.N.O.G.M.I., Università di Genova, Ospedale Policlinico San Martino, Genova, Italy; 4Pharma Ltd, Turku, Finland; Global Medical Affairs, Santen Oy, Helsinki, Finland

Related Publications

Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.


24-Hour Evaluation of the Effectiveness and Tolerability of Preservative-Free Tafluprost-Timolol Fixed Combination in Open-Angle Glaucoma or Ocular Hypertensive Patients Previously Treated with Preserved Latanoprost

Oddone F, Tanga L, Giammaria S, Sabbatini L, Strianese A, Ferrazza M, Rossetti LM


MicroRNA profile of extracellular vesicles released by Müller glial cells

Lamb W D.B.; Eastlake K.; Luis J.; Sharif N.A. ; Khaw P. T.; Limb G. A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022